Listed

InMed Pharmaceuticals Inc.

INMNasdaqCIK 1728328HealthcareFiscal year ends Jun 30

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$820.2k, Q2 FY2026
Operating income−$2.5m, Q1 FY2024
Net income−$5.8m, Q4 FY2026
InMed Pharmaceuticals Inc., income statement, quarterly
Line itemUnitQ1 FY20242023-09-30Q2 FY20242023-12-31period not labelled2024-03-31Q4 FY20242024-06-30Q1 FY20252024-09-30Q2 FY20252024-12-31Q3 FY20252025-03-31Q4 FY20252025-06-30Q1 FY20262025-09-30Q2 FY20262025-12-31Q3 FY20262026-03-31Q4 FY20262026-06-30
Revenue$k902Revenue, Q1 FY2024, three months to 2023-09-30$901.9k. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure1,240Revenue, Q2 FY2024, three months to 2023-12-31$1.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure1,173Revenue, period not labelled, three months to 2024-03-31$1.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure1,283Revenue, Q4 FY2024, three months to 2024-06-30$1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure1,265Revenue, Q1 FY2025, three months to 2024-09-30$1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure1,112Revenue, Q2 FY2025, three months to 2024-12-31$1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure1,262Revenue, Q3 FY2025, three months to 2025-03-31$1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure1,305Revenue, Q4 FY2025, three months to 2025-06-30$1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure1,120Revenue, Q1 FY2026, three months to 2025-09-30$1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure820Revenue, Q2 FY2026, three months to 2025-12-31$820.2k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figurenot reportednot reported
Cost of revenue$k881Cost of revenue, Q1 FY2024, three months to 2023-09-30$880.6k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure916Cost of revenue, Q2 FY2024, three months to 2023-12-31$916.1k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure883Cost of revenue, period not labelled, three months to 2024-03-31$883.1k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure817Cost of revenue, Q4 FY2024, three months to 2024-06-30$817.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure771Cost of revenue, Q1 FY2025, three months to 2024-09-30$771.2k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure651Cost of revenue, Q2 FY2025, three months to 2024-12-31$650.8k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure1,086Cost of revenue, Q3 FY2025, three months to 2025-03-31$1.1m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure728Cost of revenue, Q4 FY2025, three months to 2025-06-30$728.1k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure717Cost of revenue, Q1 FY2026, three months to 2025-09-30$717.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure636Cost of revenue, Q2 FY2026, three months to 2025-12-31$636.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figurenot reportednot reported
Gross profit$k21.2Gross profit, Q1 FY2024, three months to 2023-09-30$21.2k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure324Gross profit, Q2 FY2024, three months to 2023-12-31$324.1k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure289Gross profit, period not labelled, three months to 2024-03-31$289.5k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure466Gross profit, Q4 FY2024, three months to 2024-06-30$466.1k. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure493Gross profit, Q1 FY2025, three months to 2024-09-30$493.4k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure461Gross profit, Q2 FY2025, three months to 2024-12-31$460.9k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure176Gross profit, Q3 FY2025, three months to 2025-03-31$175.6k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure577Gross profit, Q4 FY2025, three months to 2025-06-30$576.7k. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure403Gross profit, Q1 FY2026, three months to 2025-09-30$403.2k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure184Gross profit, Q2 FY2026, three months to 2025-12-31$184.2k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figurenot reportednot reported
Research and development$k1,292Research and development, Q1 FY2024, three months to 2023-09-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure610Research and development, Q2 FY2024, three months to 2023-12-31$609.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure657Research and development, period not labelled, three months to 2024-03-31$656.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure659Research and development, Q4 FY2024, three months to 2024-06-30$658.9k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure700Research and development, Q1 FY2025, three months to 2024-09-30$700.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure895Research and development, Q2 FY2025, three months to 2024-12-31$895.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure425Research and development, Q3 FY2025, three months to 2025-03-31$425.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure577Research and development, Q4 FY2025, three months to 2025-06-30$577.3k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-09-09, accession 0001213900-26-098419. Derived: 12-month figure less the 9-month figure.Report this figure582Research and development, Q1 FY2026, three months to 2025-09-30$581.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure631Research and development, Q2 FY2026, three months to 2025-12-31$630.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure1,023Research and development, Q3 FY2026, three months to 2026-03-31$1.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure806Research and development, Q4 FY2026, three months to 2026-06-30$805.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-09-09, accession 0001213900-26-098419. Derived: 12-month figure less the 9-month figure.Report this figure
Operating income$k(2,537)Operating income, Q1 FY2024, three months to 2023-09-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-11-14, accession 0001213900-23-086255.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(2,537)Net income, Q1 FY2024, three months to 2023-09-30−$2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure(1,478)Net income, Q2 FY2024, three months to 2023-12-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure(1,723)Net income, period not labelled, three months to 2024-03-31−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure(1,938)Net income, Q4 FY2024, three months to 2024-06-30−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure(1,678)Net income, Q1 FY2025, three months to 2024-09-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure(2,575)Net income, Q2 FY2025, three months to 2024-12-31−$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure(2,121)Net income, Q3 FY2025, three months to 2025-03-31−$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure(1,788)Net income, Q4 FY2025, three months to 2025-06-30−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-09, accession 0001213900-26-098419. Derived: 12-month figure less the 9-month figure.Report this figure(1,727)Net income, Q1 FY2026, three months to 2025-09-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure(2,028)Net income, Q2 FY2026, three months to 2025-12-31−$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure(2,966)Net income, Q3 FY2026, three months to 2026-03-31−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure(5,839)Net income, Q4 FY2026, three months to 2026-06-30−$5.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-09, accession 0001213900-26-098419. Derived: 12-month figure less the 9-month figure.Report this figure
Diluted EPS$ per share(15.24)Diluted EPS, Q1 FY2024, three months to 2023-09-30−$15.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure(3.71)Diluted EPS, Q2 FY2024, three months to 2023-12-31−$3.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure(3.58)Diluted EPS, period not labelled, three months to 2024-03-31−$3.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figurenot reported(2.71)Diluted EPS, Q1 FY2025, three months to 2024-09-30−$2.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(3.64)Diluted EPS, Q2 FY2025, three months to 2024-12-31−$3.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure(1.94)Diluted EPS, Q3 FY2025, three months to 2025-03-31−$1.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figurenot reported(0.44)Diluted EPS, Q1 FY2026, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(0.51)Diluted EPS, Q2 FY2026, three months to 2025-12-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure(0.73)Diluted EPS, Q3 FY2026, three months to 2026-03-31−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figurenot reported
Basic EPS$ per share(15.24)Basic EPS, Q1 FY2024, three months to 2023-09-30−$15.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure(3.71)Basic EPS, Q2 FY2024, three months to 2023-12-31−$3.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure(3.58)Basic EPS, period not labelled, three months to 2024-03-31−$3.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figurenot reported(2.71)Basic EPS, Q1 FY2025, three months to 2024-09-30−$2.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(3.64)Basic EPS, Q2 FY2025, three months to 2024-12-31−$3.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure(1.94)Basic EPS, Q3 FY2025, three months to 2025-03-31−$1.94 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figurenot reported(0.44)Basic EPS, Q1 FY2026, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(0.51)Basic EPS, Q2 FY2026, three months to 2025-12-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure(0.73)Basic EPS, Q3 FY2026, three months to 2026-03-31−$0.73 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figurenot reported

Balance sheet

Cash and equivalents$5.2m, Q3 FY2026
Shareholders' equity$1.1m, FY2026
InMed Pharmaceuticals Inc., balance sheet, quarterly
Line itemUnitQ1 FY20242023-09-30Q2 FY20242023-12-31period not labelled2024-03-31FY20242024-06-30Q1 FY20252024-09-30Q2 FY20252024-12-31Q3 FY20252025-03-31FY20252025-06-30Q1 FY20262025-09-30Q2 FY20262025-12-31Q3 FY20262026-03-31FY20262026-06-30
Cash and equivalents$m6.7Cash and equivalents, Q1 FY2024, at 2023-09-30$6.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure9.5Cash and equivalents, Q2 FY2024, at 2023-12-31$9.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-02-13, accession 0001213900-24-013414.Report this figurenot reported6.6Cash and equivalents, FY2024, at 2024-06-30$6.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure5.6Cash and equivalents, Q1 FY2025, at 2024-09-30$5.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure3.4Cash and equivalents, Q2 FY2025, at 2024-12-31$3.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure4.7Cash and equivalents, Q3 FY2025, at 2025-03-31$4.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure10.7Cash and equivalents, FY2025, at 2025-06-30$10.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure9.3Cash and equivalents, Q1 FY2026, at 2025-09-30$9.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure7.0Cash and equivalents, Q2 FY2026, at 2025-12-31$7.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure5.2Cash and equivalents, Q3 FY2026, at 2026-03-31$5.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figurenot reported
Current assets$m8.3Current assets, Q1 FY2024, at 2023-09-30$8.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001213900-23-086255.Report this figure11.8Current assets, Q2 FY2024, at 2023-12-31$11.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-02-13, accession 0001213900-24-013414.Report this figurenot reported8.7Current assets, FY2024, at 2024-06-30$8.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure7.3Current assets, Q1 FY2025, at 2024-09-30$7.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure5.5Current assets, Q2 FY2025, at 2024-12-31$5.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure6.4Current assets, Q3 FY2025, at 2025-03-31$6.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure12.9Current assets, FY2025, at 2025-06-30$12.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure10.8Current assets, Q1 FY2026, at 2025-09-30$10.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure8.8Current assets, Q2 FY2026, at 2025-12-31$8.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure6.9Current assets, Q3 FY2026, at 2026-03-31$6.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure2.7Current assets, FY2026, at 2026-06-30$2.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure
Total assets$m10.9Total assets, Q1 FY2024, at 2023-09-30$10.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001213900-23-086255.Report this figure15.3Total assets, Q2 FY2024, at 2023-12-31$15.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-02-13, accession 0001213900-24-013414.Report this figurenot reported11.8Total assets, FY2024, at 2024-06-30$11.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure10.5Total assets, Q1 FY2025, at 2024-09-30$10.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure8.5Total assets, Q2 FY2025, at 2024-12-31$8.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure9.3Total assets, Q3 FY2025, at 2025-03-31$9.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure15.6Total assets, FY2025, at 2025-06-30$15.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure13.4Total assets, Q1 FY2026, at 2025-09-30$13.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure11.2Total assets, Q2 FY2026, at 2025-12-31$11.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure9.1Total assets, Q3 FY2026, at 2026-03-31$9.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure3.0Total assets, FY2026, at 2026-06-30$3.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure
Current liabilities$m1.3Current liabilities, Q1 FY2024, at 2023-09-30$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001213900-23-086255.Report this figure1.7Current liabilities, Q2 FY2024, at 2023-12-31$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-02-13, accession 0001213900-24-013414.Report this figurenot reported2.0Current liabilities, FY2024, at 2024-06-30$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure1.4Current liabilities, Q1 FY2025, at 2024-09-30$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure1.8Current liabilities, Q2 FY2025, at 2024-12-31$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure1.8Current liabilities, Q3 FY2025, at 2025-03-31$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure1.8Current liabilities, FY2025, at 2025-06-30$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure1.6Current liabilities, Q1 FY2026, at 2025-09-30$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure1.5Current liabilities, Q2 FY2026, at 2025-12-31$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure2.2Current liabilities, Q3 FY2026, at 2026-03-31$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure2.0Current liabilities, FY2026, at 2026-06-30$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure
Total liabilities$m1.3Total liabilities, Q1 FY2024, at 2023-09-30$1.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001213900-23-086255.Report this figure2.5Total liabilities, Q2 FY2024, at 2023-12-31$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-02-13, accession 0001213900-24-013414.Report this figurenot reported2.6Total liabilities, FY2024, at 2024-06-30$2.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure2.1Total liabilities, Q1 FY2025, at 2024-09-30$2.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure2.3Total liabilities, Q2 FY2025, at 2024-12-31$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure2.3Total liabilities, Q3 FY2025, at 2025-03-31$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure2.1Total liabilities, FY2025, at 2025-06-30$2.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure1.8Total liabilities, Q1 FY2026, at 2025-09-30$1.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure1.6Total liabilities, Q2 FY2026, at 2025-12-31$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure2.2Total liabilities, Q3 FY2026, at 2026-03-31$2.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure2.0Total liabilities, FY2026, at 2026-06-30$2.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(9.6)Shareholders' equity, Q1 FY2024, at 2023-09-30−$9.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure12.8Shareholders' equity, Q2 FY2024, at 2023-12-31$12.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure11.1Shareholders' equity, period not labelled, at 2024-03-31$11.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure9.2Shareholders' equity, FY2024, at 2024-06-30$9.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure8.4Shareholders' equity, Q1 FY2025, at 2024-09-30$8.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure6.2Shareholders' equity, Q2 FY2025, at 2024-12-31$6.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure7.0Shareholders' equity, Q3 FY2025, at 2025-03-31$7.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure13.4Shareholders' equity, FY2025, at 2025-06-30$13.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure11.6Shareholders' equity, Q1 FY2026, at 2025-09-30$11.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure9.6Shareholders' equity, Q2 FY2026, at 2025-12-31$9.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure6.9Shareholders' equity, Q3 FY2026, at 2026-03-31$6.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure1.1Shareholders' equity, FY2026, at 2026-06-30$1.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure

Cash flow

Operating cash flow−$3.0m, Q4 FY2026
Capital expenditure$0, Q4 FY2024
InMed Pharmaceuticals Inc., cash flow, quarterly
Line itemUnitQ1 FY20242023-09-30Q2 FY20242023-12-31period not labelled2024-03-31Q4 FY20242024-06-30Q1 FY20252024-09-30Q2 FY20252024-12-31Q3 FY20252025-03-31Q4 FY20252025-06-30Q1 FY20262025-09-30Q2 FY20262025-12-31Q3 FY20262026-03-31Q4 FY20262026-06-30
Operating cash flow$k(2,174)Operating cash flow, Q1 FY2024, three months to 2023-09-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure(1,848)Operating cash flow, Q2 FY2024, three months to 2023-12-31−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-02-12, accession 0001213900-25-013063. Derived: 6-month figure less the 3-month figure.Report this figure(1,934)Operating cash flow, period not labelled, three months to 2024-03-31−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001213900-25-042126. Derived: 9-month figure less the 6-month figure.Report this figure(1,029)Operating cash flow, Q4 FY2024, three months to 2024-06-30−$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure(1,827)Operating cash flow, Q1 FY2025, three months to 2024-09-30−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(2,502)Operating cash flow, Q2 FY2025, three months to 2024-12-31−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-11, accession 0001213900-26-014996. Derived: 6-month figure less the 3-month figure.Report this figure(1,659)Operating cash flow, Q3 FY2025, three months to 2025-03-31−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001213900-26-052920. Derived: 9-month figure less the 6-month figure.Report this figure(2,111)Operating cash flow, Q4 FY2025, three months to 2025-06-30−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-09, accession 0001213900-26-098419. Derived: 12-month figure less the 9-month figure.Report this figure(1,608)Operating cash flow, Q1 FY2026, three months to 2025-09-30−$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(2,376)Operating cash flow, Q2 FY2026, three months to 2025-12-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-11, accession 0001213900-26-014996. Derived: 6-month figure less the 3-month figure.Report this figure(1,695)Operating cash flow, Q3 FY2026, three months to 2026-03-31−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001213900-26-052920. Derived: 9-month figure less the 6-month figure.Report this figure(2,965)Operating cash flow, Q4 FY2026, three months to 2026-06-30−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-09, accession 0001213900-26-098419. Derived: 12-month figure less the 9-month figure.Report this figure
Capital expenditure$knot reportednot reported0.0Capital expenditure, period not labelled, three months to 2024-03-31$2. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0001213900-25-042126. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)4.05m, Q3 FY2026
InMed Pharmaceuticals Inc., shares, quarterly
Line itemUnitQ1 FY20232022-09-30Q2 FY20232022-12-31Q3 FY20232023-03-31Q1 FY20242023-09-30Q2 FY20242023-12-31period not labelled2024-03-31Q1 FY20252024-09-30Q2 FY20252024-12-31Q3 FY20252025-03-31Q1 FY20262025-09-30Q2 FY20262025-12-31Q3 FY20262026-03-31
Diluted shares (weighted)k shares866Diluted shares (weighted), Q1 FY2023, three months to 2022-09-30865,619 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001213900-23-086255.Report this figure2,301Diluted shares (weighted), Q2 FY2023, three months to 2022-12-312,300,526 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-02-13, accession 0001213900-24-013414.Report this figure3,328Diluted shares (weighted), Q3 FY2023, three months to 2023-03-313,328,191 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-15, accession 0001213900-23-039477.Report this figure166Diluted shares (weighted), Q1 FY2024, three months to 2023-09-30166,410 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001213900-24-098445.Report this figure399Diluted shares (weighted), Q2 FY2024, three months to 2023-12-31398,673 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-02-12, accession 0001213900-25-013063.Report this figure481Diluted shares (weighted), period not labelled, three months to 2024-03-31480,649 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure620Diluted shares (weighted), Q1 FY2025, three months to 2024-09-30620,127 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure707Diluted shares (weighted), Q2 FY2025, three months to 2024-12-31706,546 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure1,096Diluted shares (weighted), Q3 FY2025, three months to 2025-03-311,095,973 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure3,955Diluted shares (weighted), Q1 FY2026, three months to 2025-09-303,954,549 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure3,955Diluted shares (weighted), Q2 FY2026, three months to 2025-12-313,954,549 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure4,048Diluted shares (weighted), Q3 FY2026, three months to 2026-03-314,048,209 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figure

Shares outstanding: 5.49mShares outstanding, period not labelled, at 2026-09-025,493,735 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure at Sep 2, 2026, from the cover of the 10-K filed Sep 9, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.